These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 9777310)
1. Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection. Jackson CG; Williams HJ Drugs; 1998 Sep; 56(3):337-44. PubMed ID: 9777310 [TBL] [Abstract][Full Text] [Related]
2. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis. Ward JR Am J Med; 1988 Oct; 85(4A):39-44. PubMed ID: 3052055 [TBL] [Abstract][Full Text] [Related]
10. Current concepts in clinical therapeutics: disease-modifying drugs for rheumatoid arthritis. Pugh MC; Pugh CB Clin Pharm; 1987 Jun; 6(6):475-91. PubMed ID: 3319362 [TBL] [Abstract][Full Text] [Related]
11. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Schiff MH; Whelton A Semin Arthritis Rheum; 2000 Dec; 30(3):196-208. PubMed ID: 11124283 [TBL] [Abstract][Full Text] [Related]
12. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments. Simon LS Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314 [TBL] [Abstract][Full Text] [Related]
13. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739 [TBL] [Abstract][Full Text] [Related]
14. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622 [TBL] [Abstract][Full Text] [Related]
15. Commonly used disease-modifying antirheumatic drugs in the treatment of inflammatory arthritis: an update on mechanisms of action. Danning CL; Boumpas DT Clin Exp Rheumatol; 1998; 16(5):595-604. PubMed ID: 9779311 [TBL] [Abstract][Full Text] [Related]
17. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis. Nandi P; Kingsley GH; Scott DL Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of disease modifying antirheumatic drugs. Harth M J Rheumatol Suppl; 1992 Jan; 32():100-3. PubMed ID: 1613728 [TBL] [Abstract][Full Text] [Related]
19. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Nurmohamed MT; Dijkmans BA Drugs; 2005; 65(5):661-94. PubMed ID: 15748099 [TBL] [Abstract][Full Text] [Related]
20. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Rains CP; Noble S; Faulds D Drugs; 1995 Jul; 50(1):137-56. PubMed ID: 7588084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]